Analysts Issue Research Notes On Diffusion Pharmaceuticals Inc. (DFFN)

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) traded with a subtraction of -$0.02 to $0.45 on Friday, a downside of -5.02 percent. An average of 782,097 shares of common stock have been traded in the last five days. There was a fall of -$0.0295 in the past week, and it reached a new high 10 times over the past 12 months. The last 20 days have seen an average of 714,884 shares traded, while the 50-day average volume stands at 962,484.

DFFN stock has decreased by -8.33% in the last month. The company shares reached their 1-month lowest point of $0.4404 on 10/22/21. With the stock rallying to its 52-week high on 02/17/21, shares of the company touched a low of $0.45 and a high of $1.85 in 52 weeks. It has reached a new high 9 times so far this year and lost -40.62% or -$0.3463 in price. In spite of this, the price is down -75.76% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Valuation Metrics

Diffusion Pharmaceuticals Inc. (DFFN) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 33.25 for the sector. The stock’s beta is 1.44. Other valuation ratios to consider include the price-to-book (PB) ratio at 0.96.

The quick ratio of Diffusion Pharmaceuticals Inc. for the three months ended June 29 was 20.90, and the current ratio was 20.90. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Diffusion Pharmaceuticals Inc.’s return on assets was -40.20%. For the broader industry, ROE averaged -68.79 over the past year.

Earnings Surprise

In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$3.78 million in the quarter, while revenues of -$4.64 million were shrunk -34.39%. The analyst consensus anticipated Diffusion Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.04 per share, but it turned out to be -$0.04, a 0.00% surprise. For the quarter, EBITDA amounted to -$3.81 million. Shareholders own equity worth $101.9 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Diffusion Pharmaceuticals Inc. (DFFN) price momentum. RSI 9-day as of the close on 21 October was 28.77%, suggesting the stock is oversold, with historical volatility in this time frame at 36.22%.

As of today, DFFN’s price is $0.4701 -6.17% or -$0.0295 from its 5-day moving average. DFFN is currently trading -11.13% lower than its 20-day SMA and -38.11% lower than its 100-day SMA. However, the stock’s current price level is -14.65% below the SMA50 and -52.05% below the SMA200.

The stochastic %K and %D were 28.31% and 33.11%, respectively, and the average true range (ATR) was 0.0256. With the 14-day stochastic at 11.19% and the average true range at 0.0261, the RSI (14) stands at 33.37%. The stock has reached -0.0076 on the 9-day MACD Oscillator while the 14-day reading was at -0.0087.

Analyst Ratings

H.C. Wainwright downgraded Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as a Buy. The consensus rating for Diffusion Pharmaceuticals Inc. (DFFN) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell DFFN, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 0 others rate it as a “buy”.

What is DFFN’s price target for the next 12 months?

Analysts predict a range of price targets between $2.00 and $2.00, with a median target of $2.00. Taking a look at these predictions, the average price target given by analysts for Diffusion Pharmaceuticals Inc. (DFFN) stock is $2.00.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam